Difficulty: Medium
Average Score: 84%
Practice
Which of the following is a correct combination of expected pharmacological action and therapeutic use of Inhaled anticholinergics like Ipratropium?
Correct answer
A
Rationale
The correct answer is A) Blocks muscarinic receptors of the bronchi, resulting in bronchodilation. Used to treat allergen-induced and exercise-induced bronchospasm.
Rationale:
Ipratropium is an inhaled anticholinergic medication that works by blocking muscarinic receptors in the bronchi. This action leads to bronchodilation, making it an effective treatment for conditions like allergen-induced and exercise-induced bronchospasm. By inhibiting the effects of acetylcholine, which normally causes bronchoconstriction, ipratropium helps to open up the airways and improve breathing in patients with conditions like asthma and chronic obstructive pulmonary disease (COPD).
Option B is incorrect because ipratropium does not potentiate b2 adrenergic receptors to cause bronchoconstriction; rather, it acts as an anticholinergic to promote bronchodilation. Option C is incorrect as ipratropium does not block a1 cholinergic receptors or cause bronchostimulation. Option D is also incorrect as ipratropium does not potentiate b1 cholinergic receptors or induce hyperpnea; its primary effect is bronchodilation through muscarinic receptor blockade.
In an educational context, understanding the pharmacological action and therapeutic uses of hematology drugs like inhaled anticholinergics is crucial for healthcare providers managing patients with respiratory conditions. It is essential for healthcare professionals to have a solid grasp of how different medications work to select the most appropriate treatment options and optimize patient outcomes.
Rationale:
Ipratropium is an inhaled anticholinergic medication that works by blocking muscarinic receptors in the bronchi. This action leads to bronchodilation, making it an effective treatment for conditions like allergen-induced and exercise-induced bronchospasm. By inhibiting the effects of acetylcholine, which normally causes bronchoconstriction, ipratropium helps to open up the airways and improve breathing in patients with conditions like asthma and chronic obstructive pulmonary disease (COPD).
Option B is incorrect because ipratropium does not potentiate b2 adrenergic receptors to cause bronchoconstriction; rather, it acts as an anticholinergic to promote bronchodilation. Option C is incorrect as ipratropium does not block a1 cholinergic receptors or cause bronchostimulation. Option D is also incorrect as ipratropium does not potentiate b1 cholinergic receptors or induce hyperpnea; its primary effect is bronchodilation through muscarinic receptor blockade.
In an educational context, understanding the pharmacological action and therapeutic uses of hematology drugs like inhaled anticholinergics is crucial for healthcare providers managing patients with respiratory conditions. It is essential for healthcare professionals to have a solid grasp of how different medications work to select the most appropriate treatment options and optimize patient outcomes.